Today: 22 January 2026
Subscribe
Browse Category

Stocks News 2 November 2025 - 5 November 2025

Palantir Stock Skyrockets 150% – Inside the AI Defense Giant’s Epic 2025 Rally

Palantir Stock Skyrockets 150% – Inside the AI Defense Giant’s Epic 2025 Rally

Company Background and Business Model Palantir Technologies is a pioneering data analytics and software company founded in 2003 by Peter Thiel, CEO Alex Karp, and others. Originally known for its work with U.S. intelligence agencies, Palantir built its reputation developing “big data” platforms for defense and national security. Its flagship Gotham platform is widely used by government and military clients…
5 November 2025
····
COMPASS Pathways (CMPS) Psychedelic Breakthrough Stock – Latest News, Analysis & 2025 Outlook

COMPASS Pathways (CMPS) Psychedelic Breakthrough Stock – Latest News, Analysis & 2025 Outlook

Below is a full breakdown of COMPASS Pathways’ recent performance, news, expert commentary, industry positioning, and an analysis of the stock’s fundamentals, technicals, and future scenarios. Stock Performance Overview (Nov 2025) COMPASS Pathways’ stock has experienced considerable volatility in 2025, mirroring the company’s clinical trial news cycle. As of November 4, 2025, CMPS trades in the mid-$5 range (around $5.95–$6.00),…
4 November 2025
···
Ondas Holdings (ONDS) Stock Skyrockets 770% – Huge Deals, Price Swings & 2025 Outlook

Ondas Holdings (ONDS) Stock Skyrockets 770% – Huge Deals, Price Swings & 2025 Outlook

Current Stock Price & Recent Performance Chart: ONDS daily closing price, Sep–Nov 2025. After a meteoric rise in early October, the stock has retraced to the mid-$6 range. Ondas Holdings’ stock has experienced a roller coaster ride in recent weeks. After trading around $7 in late September, ONDS exploded to a 52-week high near $11.26 by October 8, 2025 Stockinvest.…
4 November 2025
···
Marriott Stock Skyrockets on Luxury Travel Boom – Full 2025 Outlook & Analysis

Marriott Stock Skyrockets on Luxury Travel Boom – Full 2025 Outlook & Analysis

Now let’s dive deeper into each of these areas and what they mean for investors considering Marriott stock in late 2025. Latest News: Earnings Beat and Forecast Boost Marriott’s third-quarter 2025 earnings (released November 4) provided a dose of good news for shareholders. Earnings per share came in at $2.47, comfortably beating Wall Street’s ~$2.39 consensus Reuters and marking a…
4 November 2025
···
Palantir’s Shocking Reinvention: From Secretive Spy Tech to $400B Cult Lifestyle Brand

Palantir Stock Whipsaws After ‘Otherworldly’ Q3—Has the 400% AI Rally Finally Met Its Match?

Key facts (Nov 4, 2025) What’s happening today (4.11.2025) Palantir (NASDAQ: PLTR) swung lower in early U.S. trading despite recording another blockbuster quarter and hiking guidance, as investors reassessed lofty AI valuations after a year‑long melt‑up. Pre‑market quotes showed the stock down nearly 7% to $192.97 as of 5:57 a.m. ET, versus Monday’s record close at $207.18.  MarketWatch The wobble…
4 November 2025
····
Kimberly-Clark’s $40 Billion Gamble Sends KMB Stock Plunging – What’s Next for This Dividend King?

Kimberly-Clark’s $40 Billion Gamble Sends KMB Stock Plunging – What’s Next for This Dividend King?

Real-Time Stock Price & Recent Performance As of November 4, 2025, Kimberly-Clark’s stock is trading around $102 per share, near its 52-week low. The current price reflects a dramatic sell-off that occurred on Monday, Nov 3, when KMB plunged from the high-$110s into the low $100s in a single session Stockanalysis. Specifically, the stock collapsed -14.57% on Nov 3 to…
4 November 2025
····
CURE Pharmaceutical (CURR) Stock Skyrockets Amid Wellness Pivot – What’s Next for Investors?

CURE Pharmaceutical (CURR) Stock Skyrockets Amid Wellness Pivot – What’s Next for Investors?

High-Flying Share Price and Recent Performance 🚀 As of November 3, 2025, CURE Pharmaceutical’s stock is trading around $3.6 per share, reflecting an explosive rise in late October. On Friday, Oct 31, the stock closed at $3.78, up from $2.89 the day prior Stockinvest. That single-day gain of +30.8% crowned CURR (now AVRW) as one of the market’s top percentage…
3 November 2025
···
TG Therapeutics Stock Soars on Briumvi Boom – Key Facts, Analyst Insights & 2025 Outlook

TG Therapeutics Stock Soars on Briumvi Boom – Key Facts, Analyst Insights & 2025 Outlook

Company Overview: Briumvi-Focused Business Model TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company specializing in treatments for B-cell mediated diseases Gurufocus. After years as a development-stage biotech, TG entered the commercial arena with Briumvi, its first approved product, and now generates the majority of revenue from Briumvi sales in the U.S. Gurufocus. The company’s strategy centers on leveraging its expertise…
3 November 2025
····
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Stock Price and Recent Performance Pfizer’s stock has languished in 2025 despite a rising broader market. At ~$24.65, PFE is roughly flat since January and far below its 2021 peak (~$50) Sharewise. In the past three years, the shares have tumbled about 50% as the company’s COVID-fueled revenue boom faded and investors braced for patent expirations Sharewise. By mid-2025, Pfizer…
3 November 2025
····
Palantir Stock Skyrockets on Massive UK AI-Defense Pact – Could PLTR Eclipse Oracle by 2030?

Palantir Stock Skyrockets to New Highs: Inside PLTR’s AI-Fueled Surge and What’s Next

Detailed Report Palantir Stock Soars to Record Highs Ahead of Earnings Palantir’s stock price has been on a tear, surging to new all-time highs as of early November 2025. As of November 3, 2025, PLTR trades around $200 per share, having gained roughly 3% in the past day and even more in pre-market trading Finbold. The stock briefly touched $204.18…
3 November 2025
····
Pfizer Stock Surges on Trump Deal & Obesity Drug Drama – Is a Comeback Coming?

Pfizer Stock Surges on Trump Deal & Obesity Drug Drama – Is a Comeback Coming?

Company Background & Significance Founded in 1849, Pfizer Inc. has grown into a pillar of the pharmaceutical industry, known for landmark drugs and vaccines. From breakthrough treatments like Lipitor (cholesterol) and Viagra (ED), to its 2020 partnership with BioNTech delivering the first approved COVID-19 vaccine, Pfizer’s innovations have had global impact. Today the company employs about 81,000 people worldwide and…
2 November 2025
···
1 … 72 73 74 75 76 … 89

Stock Market Today

  • OMRON Shares Overvalued? Analysis Shows High P/E and Weak Returns Despite Revenue Growth
    January 21, 2026, 9:23 PM EST. OMRON (TSE:6645) stocks have faced a 21.75% decline in 1-year total returns and 9.61% in 3 months despite annual revenue and net income growth. Trading at ¥3,923, it holds a high price-to-earnings (P/E) ratio of 26.9x, exceeding its fair P/E of 22.1x and the Japan Electronics sector average of 15.1x. Analyst targets remain above current prices, suggesting mixed market sentiment. Simply Wall St's discounted cash flow (DCF) model values OMRON shares significantly lower at ¥2,545.94, raising concerns of potential overvaluation. Investors face a decision weighing current market pricing against future growth potential amid mixed signals from stock performance and valuation metrics.
Go toTop